Master-class “Pharmacological methods for prognosis improvement for patients with chronic cardiac failure”

SANTO organizes “Pharmacological methods for prognosis improvement for patients with chronic cardiac failure”, a master-class with participation of top-level scientists, and cardiologists from Kazakhstan and Russia. Master-classes were conducted: on January 22 – in Almaty, on January 23 – in Shymkent, and on January 25 – in Astana.

Nowadays, cardiovascular mortality (CVM) is one of the main reasons of total mortality in Kazakhstan. The main risk group includes patients with chronic heart failure (CHF). Delayed diagnosis of: a disease, serious comorbidity with electrolyte imbalance, diabetes mellitus, obesity, and anemia are persistent problems for cardiologists. Health statistics show that CHF development is conditioned very often by arterial hypertension (AH), CHD, rheumatic heart diseases and anemia of different origins.  According to epidemiological data, 4% of the population in Kazakhstan is diagnosed with CHF as a complication of the majority of cardiovascular diseases, especially arterial hypertension and ischemic heart disease. According to WHO, the mortality rate in the Republic of Kazakhstan, which is due to circulatory system diseases, is two times higher than in European countries. Over the past decade, cardiovascular morbidity rate increased by 1.7 percent in Kazakhstan. There is also data on the fourfold increase in hospital admission rates due to CHD which was compared to the rates of the past 20 years.

During the master-class, the report on the following topic, “The Importance of CHD epidemiology in the Republic of Kazakhstan” was presented by G. Dzhunusbekova, M.D., Prof., Deputy Director for Scientific Activities, Deputy Director for Postgraduate Education and Science, Research Institute for Cardiology and General Medicine RSE REU of the Ministry of Health of the Republic of Kazakhstan. The modern pharmacological methods for prognosis improvement for patients with chronic cardiac failure were presented by F. Ageyev, M.D., Prof., Head of Scientific and Follow-up Department Research Institute for Cardiology in the name of Myasnikov, the member of the Society of cardiology of Russian Federation (VNOK), one of organizers of “Society for Cardiac Failure”, SCF schools for cardiac failure. The leading specialists and cardiologists: M. Tundybayeva, S. Abseitova, G.Zhusupova, M.Mukarova, G.Alipova, R.Almukhambetova, Sh.Zhangelova, K.Karibayeva participated in panel discussions.

------------------------------------------------------------------------------------------------------------------------------------------

ABOUT SANTO:                                                                    

SANTO Member of Polpharma Group is the trademark of Chimpharm JSC (KASE: CHFM). The Company develops, manufactures and supplies markets located in Kazakhstan and Central Asia with affordable and high quality medical products. The Company’s production capacity enables the annual manufacturing of 600 million tablets, 300 million ampoules, 6 million infusions, 40 million vials of antibiotics and 26 million vials of syrups. The company is the leader of the Kazakh pharmaceutical market with its portfolio that includes over 200 generic drugs which are used in 12 different therapeutic categories for treatment of diseases in various therapeutic fields. SANTO Company is the responsible employer for over 1000 employees in Shymkent and all regions of the Republic of Kazakhstan. The Company exports its products into countries such as Turkmenistan, Kyrgyzstan, Mongolia, Tajikistan, Russia, and Ukraine.

Tatiana Filipchik, PR-manager

SANTO Company

Address: 19 floor, block 5B, Nurly-Tau PFC, 17/1 Al Farabi Ave., Almaty 050013, Kazakhstan

Tel.: +7 (727) 3121833

e-mail: tatyana.filipchik@santo.kz

www.santo.kz   

It may be interesting